A new study shows that women with high grade serous ovarian cancer who remain cancer free for 7 years or more had nearly the same mortality risk as the general U.S. population. Of note, most of the women in this study had stage 3 ovarian cancer.
Those with homologous repair deficiency (HRD) ovarian tumors (which is present in BRCA1/2 carriers) had substantially higher survival than those without HRD, both at 5 and 10 years out from their diagnosis:
- Event-Free Survival at 5 years (24.3% versus 14.7%) and 10 years (15.5% versus 8.9%)
- Overall Survival at 5 years (54.6% vs 34.9%) and 10 years (28.4% vs 16.8%)
This means that once an ovarian cancer survivor has reached the 7 year mark and is cancer free, their mortality rates are similar to that of the U.S. general population.
Learn more at https://pmc.ncbi.nlm.nih.gov/articles/PMC13035374/
Reference: De Vitis et al. JCO Oncol Adv. 2026;3(1):e2500142. PMID: 41918500
Through ICARE, we aspire to share cancer-related information that may be of interest. If you have questions or clarifications, please direct them to your healthcare provider.
